Category: Clinical

Zepbound (tirzepatide) superior to Wegovy (semaglutide), says Lilly-funded clinical trial

December 4, 2024

•

Investor Empires

In the midst of the war on obesity, a clear winner has emerged in the battle between two weight-loss injections. Zepbound (tirzepatide), made by Fortune 500 company Eli Lilly & Co., outperformed competitor Wegovy (semaglutide), a Novo Nordisk Top 500 product, in a recent study Randomized clinical trial Supported by…
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lun

October 12, 2024

•

Investor Empires

The first scientific presentation of previously announced data from Cohort 1 of an ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg twice daily) in IPF, confirms positive trends in seven of the eight biomarkers evaluated, suggesting to a potential therapeutic effect Enrollment in the second cohort evaluating high-dose…
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

September 14, 2024

•

Investor Empires

Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase…
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

July 9, 2024

•

Investor Empires

This section is Partnership Content Provided The content in this section has been provided by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Globe Newswire Breadcrumbs Path Links Globe Newswire Article author: Published on July 9, 2024 •…
Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

June 10, 2024

•

Investor Empires

Article content VIENNA — AOP Orphan Pharmaceuticals GmbH (AOP Health) continues a successful clinical research program in hematology/oncology by accepting two abstracts for presentation at the 2024 European Hematology Association (EHA) Hybrid Congress in Madrid, Spain. One leads to an oral presentation of the latest results from the PROUD-PV and…
JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

May 29, 2024

•

Investor Empires

This section is Partnership content provided The content in this section is provided by Business Wire for the purposes of press release distribution on behalf of its clients. Postmedia has not reviewed the content. by Business wire Breadcrumb links PMN press releases Business newsletters Article writer: Posted on May 29,…
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention By Investing.com

May 11, 2024

•

bitlyfool

new Taipei city, May 11, 2024 /PRNewswire/ — Calliway Biopharmaceuticals (Calliway) is pleased to announce its partnership to share the latest clinical developments in the upcoming 2024 year Vital International Convention on Wednesday, June 5in 11:45 AM PT. The presentation will take place at Theater show company 2 in San…